HARBIN, China, Aug. 28 /PRNewswire-Asia/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company's 2009 Annual Meeting of Shareholders will be held on Thursday, September 24, 2009 at Harbin Shen Te Hotel which is in close proximity to the Company's headquarters in Harbin, China. The proxy materials and annual report on Form 10-K are available on the Company's website http://www.cski.com.cn .
The time and venue of China Sky One Medical's Annual Meeting are as follows:
Date: Thursday, September 24, 2009
Time: 9:30 am (Beijing Time)
Venue: No. 58, Gan Shui Road, Nangang District, Harbin,
People's Republic of China 150090
At the annual meeting the following two proposals will be submitted for shareholders' approval, fully described in the Proxy Statement issued on August 26, 2009.
1. To elect seven (7) directors, as described in the Proxy Statement; and
2. To transact such other business as may properly come before the
Annual Meeting.
China Sky One Medical's executives will provide an investor presentation to discuss the Company's growth strategy, business outlook, and financial performance. The Company's management and Board members will also accept questions from analysts and investors. For those unable to attend the annual meeting, a video record will be available on the Company's website from September 25, 2009.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR''), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the annual meeting of shareholders. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Stanley Hao, CFO
Tel: +86-451-5399-4069
Email: stanleyhao@cski.com.cn
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
